These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 30721710)

  • 1. Physiologically Based Pharmacokinetic Modeling to Supplement Nilotinib Pharmacokinetics and Confirm Dose Selection in Pediatric Patients.
    Heimbach T; Lin W; Hourcade-Potelleret F; Tian X; Combes FP; Horvath N; He H
    J Pharm Sci; 2019 Jun; 108(6):2191-2198. PubMed ID: 30721710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigating the Role of Altered Systemic Albumin Concentration on the Disposition of Theophylline in Adult and Pediatric Patients with Asthma by Using the Physiologically Based Pharmacokinetic Approach.
    Rasool MF; Khalid R; Imran I; Majeed A; Saeed H; Alasmari F; Alanazi MM; Alqahtani F
    Drug Metab Dispos; 2020 Jul; 48(7):570-579. PubMed ID: 32393652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens.
    Cohen-Rabbie S; Zhou L; Vishwanathan K; Wild M; Xu S; Freshwater T; Jain L; Schalkwijk S; Tomkinson H; Zhou D
    J Clin Pharmacol; 2021 Nov; 61(11):1493-1504. PubMed ID: 34196005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically Based Pharmacokinetic Modeling and Simulation of Sunitinib in Pediatrics.
    Yu Y; DuBois SG; Wetmore C; Khosravan R
    AAPS J; 2020 Jan; 22(2):31. PubMed ID: 31975150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug-Drug Interactions or in Special Populations: An Example Using Tofacitinib.
    Tse S; Dowty ME; Menon S; Gupta P; Krishnaswami S
    J Clin Pharmacol; 2020 Dec; 60(12):1617-1628. PubMed ID: 32592424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically Based Pharmacokinetic Modeling of Nilotinib for Drug-Drug Interactions, Pediatric Patients, and Pregnancy and Lactation.
    Liu XI; Leong R; Burckart GJ; Dallmann A
    J Clin Pharmacol; 2024 Mar; 64(3):323-333. PubMed ID: 37909674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically-Based Pharmacokinetic Modeling to Investigate the Effect of Maturation on Buprenorphine Pharmacokinetics in Newborns with Neonatal Opioid Withdrawal Syndrome.
    van Hoogdalem MW; Johnson TN; McPhail BT; Kamatkar S; Wexelblatt SL; Ward LP; Christians U; Akinbi HT; Vinks AA; Mizuno T
    Clin Pharmacol Ther; 2022 Feb; 111(2):496-508. PubMed ID: 34679189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
    Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
    Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologically Based Pharmacokinetic Modeling of Oxycodone in Children to Support Pediatric Dosing Optimization.
    Zheng L; Xu M; Tang SW; Song HX; Jiang XH; Wang L
    Pharm Res; 2019 Oct; 36(12):171. PubMed ID: 31654287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Model-Informed Pediatric Dose Selection for Dapagliflozin by Incorporating Developmental Changes.
    Jo H; Pilla Reddy V; Parkinson J; Boulton DW; Tang W
    CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):108-118. PubMed ID: 33439535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia.
    Giles FJ; Yin OQ; Sallas WM; le Coutre PD; Woodman RC; Ottmann OG; Baccarani M; Kantarjian HM
    Eur J Clin Pharmacol; 2013 Apr; 69(4):813-23. PubMed ID: 23052406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling.
    Li GF; Wang K; Chen R; Zhao HR; Yang J; Zheng QS
    Acta Pharmacol Sin; 2012 Nov; 33(11):1359-71. PubMed ID: 23085739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Model qualification of the PK-Sim® pediatric module for pediatric exposure assessment of CYP450 metabolized compounds.
    Yun YE; Edginton AN
    J Toxicol Environ Health A; 2019; 82(14):789-814. PubMed ID: 31405354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Physiologically Based Pharmacokinetic Model to Describe Artemether Pharmacokinetics in Adult and Pediatric Patients.
    Lin W; Heimbach T; Jain JP; Awasthi R; Hamed K; Sunkara G; He H
    J Pharm Sci; 2016 Oct; 105(10):3205-3213. PubMed ID: 27506269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Verification of a Full Physiologically Based Pharmacokinetic Model for Sublingual Buprenorphine in Healthy Adult Volunteers that Accounts for Nonlinear Bioavailability.
    van Hoogdalem MW; Tanaka R; Johnson TN; Vinks AA; Mizuno T
    Drug Metab Dispos; 2024 Jul; 52(8):785-796. PubMed ID: 38769016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug.
    Khalil F; Läer S
    AAPS J; 2014 Mar; 16(2):226-39. PubMed ID: 24399240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
    Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
    Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles.
    Peters SA
    Clin Pharmacokinet; 2008; 47(4):245-59. PubMed ID: 18336054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide.
    Narayanan R; Hoffmann M; Kumar G; Surapaneni S
    Drug Metab Lett; 2016; 10(3):172-179. PubMed ID: 27604990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetics of Brentuximab Vedotin in Adult and Pediatric Patients With Relapsed/Refractory Hematologic Malignancies: Model-Informed Hypothesis Generation for Pediatric Dosing Regimens.
    Suri A; Mould DR; Song G; Kinley J; Venkatakrishnan K
    J Clin Pharmacol; 2020 Dec; 60(12):1585-1597. PubMed ID: 32596842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.